| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
PRE-084 hydrochloride (0.1-100 μM; 24 hours) protects cultured cortical neurons from beta-amyloid poisoning (maximal neuroprotection at 10 μM) and lowers pro-apoptotic proteins at 10 μM Bax level[1].
|
|---|---|
| ln Vivo |
In wobbler mice, PRE-084 hydrochloride (0.25 mg/kg; i.p.; three times per week for eight weeks) demonstrated positive effects on locomotor performance (better grip performance, reduced paw abnormalities, and increased motor neuron survival), as well as neuroprotective effects (higher levels of BDNF in gray matter) [2]. ?By stimulating the Akt, PRE-084 hydrochloride (1 mg/kg; intraperitoneal injection; single dose) guards the heart.A model of myocardial infarction using the eNOS pathway [3].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Cortical cells (βAP(25-35) induced neurotoxicity model) Tested Concentrations: 0.1-100 µM Incubation Duration: 24 hrs (hours) Experimental Results: diminished neuronal toxicity in a bell-shaped manner and at 10 µM . Western Blot Analysis[1] Cell Types: Cortical cells (βAP(25-35)-induced neurotoxicity model) Tested Concentrations: 10 µM Incubation Duration: 24 h Experimental Results: βAP(25--induced pro-apoptotic protein Bax in cortical neurons Level diminished by 35). |
| Animal Protocol |
Animal/Disease Models: Wobbler mouse (4 weeks old) [2].
Doses: 0.25 mg/kg Route of Administration: intraperitoneal (ip) injection; 3 times a week for 8 weeks. Experimental Results: Paw abnormalities were Dramatically improved from week 4 onwards, and paw grip strength was Dramatically improved by week 5. The number of reactive astrocytes diminished, while the number of panmacrophage markers CD68-positive cells and CD206+ cells involved in tissue repair increased. Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat (220-250 g; myocardial infarction model) [3]. Doses: 1 mg/kg Route of Administration: intraperitoneal (ip) injection; single. Experimental Results: The degree of cardiomyocyte apoptosis was Dramatically diminished. Resulting in a significant increase in p-Akt and p-eNOS expression. |
| References |
|
| Molecular Formula |
C19H27NO3.HCL
|
|---|---|
| Molecular Weight |
353.884
|
| Exact Mass |
353.175
|
| CAS # |
75136-54-8
|
| Related CAS # |
PRE-084;138847-85-5
|
| PubChem CID |
11314197
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.503
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
24
|
| Complexity |
367
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QUJWFJNHTBKCLU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H27NO3.ClH/c21-18(23-16-13-20-11-14-22-15-12-20)19(9-5-2-6-10-19)17-7-3-1-4-8-17;/h1,3-4,7-8H,2,5-6,9-16H2;1H
|
| Chemical Name |
2-morpholin-4-ylethyl 1-phenylcyclohexane-1-carboxylate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 34 mg/mL (~96.08 mM)
H2O : ~33.33 mg/mL (~94.18 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8258 mL | 14.1291 mL | 28.2582 mL | |
| 5 mM | 0.5652 mL | 2.8258 mL | 5.6516 mL | |
| 10 mM | 0.2826 mL | 1.4129 mL | 2.8258 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
